INmune Bio Inc. - Common stock (INMB)

Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.

INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027. Ch

INmune Bio (INMB) Q4 2025 Earnings Transcript

INmune Bio (INMB) Q1 2026 Earnings Transcript

INmune Bio (INMB) reported a narrower-than-expected Q3 2025 loss, sparking a positive after-hours market reaction for the clinical-stage biotech firm.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

The trading volume of these stocks is deviating from the norm in today's session.

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint.